Quarterly report · Q3
3353.TEDINET S100SM34
Period2023-03-01 → 2023-11-30
Filed2024-01-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥28.8bn | 2023-03-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.4bn | 2022-03-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2023-03-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | ¥706m | 2022-03-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2023-03-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥888m | 2022-03-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.3bn | 2023-03-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥998m | 2022-03-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥812m | 2023-03-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥597m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥847m | 2023-03-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | ¥623m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥32.8bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥28.0bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥19.4bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥14.9bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥13.4bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥12.4bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.8bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥216.2 | 2023-03-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.93 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥159 | 2022-03-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.34 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-11-30 | −¥670m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-11-30 | −¥670m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-11-30 | −¥544m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥17.7bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥17.7bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥1.3bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥160m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥5.7bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥5.1bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥666m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥99m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥140m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥136m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥3m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥99m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-11-30 | ¥29.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-11-30 | ¥28.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥670m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-11-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-11-30 | −¥557m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥1.1bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥35m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥2.2bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥742m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥29m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥142m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥1m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥92m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-11-30 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-11-30 | ¥25.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥744m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-11-30 | ¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 370
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人ト ー マ ツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)神 野 敦 生 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)牧 野 秀 俊 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 25427609000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 28769800000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 33897598000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 888109000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 1190677000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1227454000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 597303000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 812423000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 759598000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 612374000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 959357000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 827629000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 12392588000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 13403564000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 12607842000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 27975422000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 32765530000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 27505776000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 159.00 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 216.20 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 202.20 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.423 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.391 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.438 | |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 59.34 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 97.93 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4070000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 311800 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 3757200 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 37572 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 1000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 4070000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 37572 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 311800 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |